About: CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2018 (uk) artículu científicu espublizáu en mayu de 2018 (ast) scientific article published on 01 May 2018 (en)
publication date	wds:Q61776042-298EF546-F4DE-4355-8B53-5CB16E5C0312
publication date	2018-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q61776042-E240C9B9-5EB2-4F7B-8678-9A928055417B
language of work or name	English
cites work	wds:Q61776042-14EAE0C3-9C25-4010-9DFF-2F682D9FFD2A wds:Q61776042-15DD90F5-32CD-4996-8C87-FA194E3594B3 wds:Q61776042-284C9013-15F7-4B9A-8BFE-E4B0D1F38E74 wds:Q61776042-3FFCAC74-3B58-4122-B792-4E952CEAEF4E wds:Q61776042-49A2C511-677C-47B3-A4AE-8B763B07BC22 wds:Q61776042-51223C41-B23E-47AF-9FB1-4D520D33306C wds:Q61776042-5C4B13F1-3251-4E09-9E6F-38E517DF19FF wds:Q61776042-5F2F91C1-51E7-41DB-BEE7-6682A27C820B wds:Q61776042-6232CBD6-19EB-45D8-A802-8E9D8D1E2E1A wds:Q61776042-63B5F017-13BA-447B-8B23-065AC7115AE4 wds:Q61776042-6F38694F-0129-4513-BFF2-444F894250AF wds:Q61776042-7AF8031D-280D-4CC2-B0DD-0B563BC45FFC wds:Q61776042-8B881438-B850-43E2-B976-6550BF140E66 wds:Q61776042-8F4B7B77-CAD2-4A4E-AEA7-9069AE728297 wds:Q61776042-978CC8CC-2AF4-435A-BD7E-8B490ED3E519 wds:Q61776042-9C5AF875-84F1-426E-AA46-0DC194B1C30F wds:Q61776042-A5DF7CD7-5384-475A-AA10-686CCBEF24FB wds:Q61776042-BCF0216D-EF2F-4E5A-8D15-A27F1DF769FB wds:Q61776042-BF4E16EA-C677-4474-8C96-A7FB1329F672 wds:Q61776042-BF5AD398-196C-40EB-B5E8-8653D1769880 wds:Q61776042-D508FCCA-ADD1-4AB1-95F4-92608909A0F0 wds:Q61776042-DB7889DB-E00D-459D-92DF-880A7D08D0EB wds:Q61776042-E74E68D8-CF64-4197-B6B3-347E10FCB044
cites work	CIP2A inhibits PP2A in human malignancies Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation The protein kinase B/Akt signalling pathway in human malignancy Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. CIP2A is associated with human breast cancer aggressivity Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression CIP2A expression is increased in prostate cancer Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes The AKT kinase is activated in multiple myeloma tumor cells c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
author name string	wds:Q61776042-106E2537-A5EC-4073-A36C-1795973D6EF2 wds:Q61776042-5001C040-2257-404F-92A2-3D8A4B001D66 wds:Q61776042-9C61AEB8-0C70-466F-BA50-04030C3F0697 wds:Q61776042-A3C78196-3E79-40C3-BB00-0D72BD210945 wds:Q61776042-CDB784BB-E16D-4FCA-8732-8FDCBD9F3CF3 wds:Q61776042-DBE21EEE-C8F6-4BD4-928D-03A901C6AA7F
author name string	Laura J Scott Alan K Burnett Robert K Hills Richard E Clark Natasha Carmell Alison K Holcroft
rdfs:label	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (en) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (nl)
skos:prefLabel	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (en) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (nl)
name	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (en) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (nl)
author	wds:Q61776042-914B41C1-373E-4DD0-BB15-C8A12D6DAC74
author	Claire M Lucas
title	wds:Q61776042-A818A536-70CC-42DA-9B2A-A5BC06F28DC4
title	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (en)
page(s)	wds:Q61776042-680C03AD-A286-47AB-807E-34839DA85E04
page(s)	964-968
instance of	wds:Q61776042-24506E73-9CB6-4947-AD9D-77B5E14A528C
instance of	scholarly article
main subject	wds:Q61776042-14E1BA91-5FDB-4537-B30F-E636D5FC031D wds:Q61776042-5684682F-C9CF-4CE1-8163-C37481B3E315
main subject	phosphorylation biomarker
PubMed ID	wds:Q61776042-973BE616-0E97-4333-8A60-B00C94541AF2
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29703716
PubMed ID	29703716
issue	wds:Q61776042-DF207DB5-7EAA-436F-914E-F0D684A0A9B2
volume	wds:Q61776042-7021F2BB-A129-49BF-B1ED-CE32611BD890
issue	9
volume	2
DOI	wds:Q61776042-5E0C9DBE-5F8C-4E24-91E5-9C4237820C4D
DOI	http://dx.doi.org/10.1182/BLOODADVANCES.2017013615
DOI	10.1182/BLOODADVANCES.2017013615
PMCID	wds:Q61776042-59F047F2-E461-4CB5-BC6B-72A0D9413D01
PMCID	5941996
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q61776042
is cites work of	The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software